JP2025510774A - 修飾ｆｃドメインを有するｓｉｒｐ－ａｌｐｈａ融合ポリペプチド - Google Patents

修飾ｆｃドメインを有するｓｉｒｐ－ａｌｐｈａ融合ポリペプチド Download PDF

Info

Publication number
JP2025510774A
JP2025510774A JP2024556407A JP2024556407A JP2025510774A JP 2025510774 A JP2025510774 A JP 2025510774A JP 2024556407 A JP2024556407 A JP 2024556407A JP 2024556407 A JP2024556407 A JP 2024556407A JP 2025510774 A JP2025510774 A JP 2025510774A
Authority
JP
Japan
Prior art keywords
domain
fusion polypeptide
fold
modified
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510774A5 (https=
Inventor
フォルクマー，イェンス－ペーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bitterroot Bio Inc
Original Assignee
Bitterroot Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bitterroot Bio Inc filed Critical Bitterroot Bio Inc
Publication of JP2025510774A publication Critical patent/JP2025510774A/ja
Publication of JP2025510774A5 publication Critical patent/JP2025510774A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024556407A 2022-03-24 2023-03-23 修飾ｆｃドメインを有するｓｉｒｐ－ａｌｐｈａ融合ポリペプチド Pending JP2025510774A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263323417P 2022-03-24 2022-03-24
US63/323,417 2022-03-24
PCT/US2023/064886 WO2023183892A1 (en) 2022-03-24 2023-03-23 Sirp-alpha fusion polypeptides with modified fc domains

Publications (2)

Publication Number Publication Date
JP2025510774A true JP2025510774A (ja) 2025-04-15
JP2025510774A5 JP2025510774A5 (https=) 2026-03-30

Family

ID=86054071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556407A Pending JP2025510774A (ja) 2022-03-24 2023-03-23 修飾ｆｃドメインを有するｓｉｒｐ－ａｌｐｈａ融合ポリペプチド

Country Status (13)

Country Link
US (1) US20230365648A1 (https=)
EP (1) EP4499837A1 (https=)
JP (1) JP2025510774A (https=)
KR (1) KR20240162572A (https=)
CN (1) CN119546769A (https=)
AU (1) AU2023240361A1 (https=)
CA (1) CA3246192A1 (https=)
CL (1) CL2024002849A1 (https=)
CO (1) CO2024013909A2 (https=)
IL (1) IL315706A (https=)
JO (1) JOP20240212A1 (https=)
MX (1) MX2024011528A (https=)
WO (1) WO2023183892A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
US10011660B2 (en) * 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
PL3575326T3 (pl) * 2012-12-17 2022-07-11 Pf Argentum Ip Holdings Llc Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
PL3180363T3 (pl) 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
AU2016304794B2 (en) 2015-08-07 2021-07-15 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
CN116239698A (zh) * 2019-03-06 2023-06-09 江苏恒瑞医药股份有限公司 双功能融合蛋白及其医药用途
EP3976658A4 (en) * 2019-05-24 2023-06-07 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
WO2020263830A1 (en) * 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use

Also Published As

Publication number Publication date
CO2024013909A2 (es) 2024-10-31
AU2023240361A1 (en) 2024-10-03
JOP20240212A1 (ar) 2024-09-29
CL2024002849A1 (es) 2025-05-23
KR20240162572A (ko) 2024-11-15
CA3246192A1 (en) 2023-09-28
WO2023183892A1 (en) 2023-09-28
IL315706A (en) 2024-11-01
EP4499837A1 (en) 2025-02-05
MX2024011528A (es) 2024-12-06
US20230365648A1 (en) 2023-11-16
CN119546769A (zh) 2025-02-28

Similar Documents

Publication Publication Date Title
US9840554B2 (en) Antibodies against platelet-derived growth factor (PDGF)
JP7713051B2 (ja) 抗ｎｐｒ１抗体およびその使用
JP7084045B2 (ja) Ｃｄ４７抗体およびサイトカインを含む融合タンパク質
JP6410712B2 (ja) Ｉｌ−６結合分子
CN1259972C (zh) 抗凝剂和人源化抗冯·维勒布兰德氏因子的单克隆抗体
US20230074436A1 (en) Anti-alpha-synuclein antibodies and methods of use thereof
JP2025518061A (ja) 抗ｂｄｃａ２抗体およびその使用
KR20240137640A (ko) 항-cd3 및 항-cd20 이중특이성 항체 및 이의 용도
JP2019510474A (ja) トロンビン抗体、その抗原結合フラグメント及び医薬用途
JP2021527424A (ja) 抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用
JP2025514939A (ja) Ｃｄ３／ｂｃｍａ／ｃｄ３８三重特異性抗体
JP2024542823A (ja) アンタゴニスト抗ｎｐｒ１抗体およびその使用方法
JP2025510774A (ja) 修飾ｆｃドメインを有するｓｉｒｐ－ａｌｐｈａ融合ポリペプチド
US20250257113A1 (en) Multivalent sirp-alpha fusion polypeptides
IL324435A (en) Anti-il1rap antibodies
KR20240004332A (ko) 폰 빌레브란트 인자(vwf) 억제제
JP2026071208A (ja) Ｂｃｍａに結合する多重特異性抗体
CN121175339A (zh) 抗fxi抗体及其用途
EA052748B1 (ru) Антагонистические анти-npr1 антитела и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260319